These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 35530323)
1. Acceptability of Drugs in the Treatment of Unresectable/Metastatic BRAF V600-Mutant Melanoma: A Systematic Review and Network Meta-Analysis. Hong L; Huang P; Zheng X; Ye X; Zhao H; Wang J; Shao Y Front Oncol; 2022; 12():865656. PubMed ID: 35530323 [TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis. Corrie P; Meyer N; Berardi R; Guidoboni M; Schlueter M; Kolovos S; Macabeo B; Trouiller JB; Laramée P Cancer Treat Rev; 2022 Nov; 110():102463. PubMed ID: 36099854 [TBL] [Abstract][Full Text] [Related]
3. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. Franken MG; Leeneman B; Gheorghe M; Uyl-de Groot CA; Haanen JBAG; van Baal PHM Eur J Cancer; 2019 Dec; 123():58-71. PubMed ID: 31670077 [TBL] [Abstract][Full Text] [Related]
4. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients. Daud A; Gill J; Kamra S; Chen L; Ahuja A J Hematol Oncol; 2017 Jan; 10(1):3. PubMed ID: 28052762 [TBL] [Abstract][Full Text] [Related]
5. BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis. Garutti M; Bergnach M; Polesel J; Palmero L; Pizzichetta MA; Puglisi F Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612138 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of dabrafenib-trametinib in the treatment of unresectable or metastatic melanoma with BRAF V600 mutation: A systematic review and network meta-analysis. Garzón-Orjuela N; Prieto-Pinto L; Lasalvia P; Herrera D; Castrillón J; González-Bravo D; Castañeda-Cardona C; Rosselli D Dermatol Ther; 2020 Aug; ():e14135. PubMed ID: 32761749 [TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison. Atkins MB; Tarhini A; Rael M; Gupte-Singh K; O'Brien E; Ritchings C; Rao S; McDermott DF Immunotherapy; 2019 May; 11(7):617-629. PubMed ID: 30852924 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of dabrafenib-trametinib in the treatment of unresectable advanced/metastatic melanoma with BRAF-V600 mutation: A systematic review and network meta-analysis. Garzón-Orjuela N; Prieto-Pinto L; Lasalvia P; Herrera D; Castrillón J; González-Bravo D; Castañeda-Cardona C; Rosselli D Dermatol Ther; 2020 Mar; 33(2):e13145. PubMed ID: 31664762 [TBL] [Abstract][Full Text] [Related]
9. Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis. Boutros A; Tanda ET; Croce E; Catalano F; Ceppi M; Bruzzone M; Cecchi F; Arecco L; Fraguglia M; Pronzato P; Genova C; Del Mastro L; Lambertini M; Spagnolo F Eur J Cancer; 2023 Jul; 188():64-79. PubMed ID: 37196485 [TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of combined ipilimumab and nivolumab versus ipilimumab in patients with Stage III/IV unresectable melanoma: A systematic review and meta-analysis. Zhu Y; Cheng H; Zhong M; Hu Y; Li Q; Gao X; Liu S J Cancer Res Ther; 2021 Dec; 17(7):1679-1688. PubMed ID: 35381739 [TBL] [Abstract][Full Text] [Related]
11. A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma Tarhini AA; Toor K; Chan K; McDermott DF; Mohr P; Larkin J; Hodi FS; Lee CH; Rizzo JI; Johnson H; Moshyk A; Rao S; Kotapati S; Atkins MB ESMO Open; 2021 Apr; 6(2):100050. PubMed ID: 33556898 [TBL] [Abstract][Full Text] [Related]
12. Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for Hamid O; Cowey CL; Offner M; Faries M; Carvajal RD Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31653096 [TBL] [Abstract][Full Text] [Related]
13. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941 [TBL] [Abstract][Full Text] [Related]
14. Adjuvant therapy for cutaneous melanoma: a systematic review and network meta-analysis of new therapies. Longo C; Pampena R; Lallas A; Kyrgidis A; Stratigos A; Peris K; Garbe C; Pellacani G J Eur Acad Dermatol Venereol; 2020 May; 34(5):956-966. PubMed ID: 31721319 [TBL] [Abstract][Full Text] [Related]
15. The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era. Vanella V; Festino L; Trojaniello C; Vitale MG; Sorrentino A; Paone M; Ascierto PA Curr Oncol Rep; 2019 Jul; 21(9):76. PubMed ID: 31359162 [TBL] [Abstract][Full Text] [Related]
16. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation. Dhillon S Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822 [TBL] [Abstract][Full Text] [Related]
17. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628 [TBL] [Abstract][Full Text] [Related]